CR20170096A - Tratamientos conjuntos con anticuerpos anti cd40 - Google Patents

Tratamientos conjuntos con anticuerpos anti cd40

Info

Publication number
CR20170096A
CR20170096A CR20170096A CR20170096A CR20170096A CR 20170096 A CR20170096 A CR 20170096A CR 20170096 A CR20170096 A CR 20170096A CR 20170096 A CR20170096 A CR 20170096A CR 20170096 A CR20170096 A CR 20170096A
Authority
CR
Costa Rica
Prior art keywords
treatments
antibodies
joint
joint treatments
antibody
Prior art date
Application number
CR20170096A
Other languages
English (en)
Inventor
Peter; Ellmark
Niina Veitonmäki
Per; Norlen
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of CR20170096A publication Critical patent/CR20170096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a tratamientos conjuntos para tratar un tumor sólido en un sujeto. Los tratamientos conjuntos comprenden (a) un anticuerpo, o la porción de fijación al antígeno de este, que se fija específicamente a CD40, y (b) un agente inmunoterapéutico adicional con eficacia en el tratamiento del cáncer, en donde el agente no es un anticuerpo anti- CD40 ni el fragmento de fijación al antígeno de este. La invención también se refiere a kits y métodos para usar tales tratamientos.
CR20170096A 2014-08-12 2015-08-12 Tratamientos conjuntos con anticuerpos anti cd40 CR20170096A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB201422614 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies
PCT/EP2015/068598 WO2016023960A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies

Publications (1)

Publication Number Publication Date
CR20170096A true CR20170096A (es) 2017-06-15

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170096A CR20170096A (es) 2014-08-12 2015-08-12 Tratamientos conjuntos con anticuerpos anti cd40

Country Status (25)

Country Link
US (3) US11149090B2 (es)
EP (2) EP3552665A3 (es)
JP (1) JP6654187B2 (es)
KR (1) KR102443258B1 (es)
CN (2) CN106573981A (es)
AU (1) AU2015303164B2 (es)
CA (1) CA2957146A1 (es)
CL (1) CL2017000335A1 (es)
CO (1) CO2017001317A2 (es)
CR (1) CR20170096A (es)
DK (1) DK3180087T3 (es)
EA (1) EA201790339A1 (es)
EC (1) ECSP17008984A (es)
ES (1) ES2725463T3 (es)
IL (1) IL250512B (es)
MA (1) MA47472A (es)
MX (1) MX2017001864A (es)
NI (1) NI201700015A (es)
NZ (1) NZ729270A (es)
PE (1) PE20170680A1 (es)
PH (1) PH12017500229A1 (es)
SG (1) SG11201701070WA (es)
SV (1) SV2017005380A (es)
UA (1) UA119783C2 (es)
WO (1) WO2016023960A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
PT3081576T (pt) 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
KR102410778B1 (ko) * 2016-05-13 2022-06-21 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
KR20240017129A (ko) * 2016-07-14 2024-02-06 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
JP7265989B2 (ja) 2016-10-25 2023-04-27 ウロゲン ファーマ リミテッド 体腔の免疫調節治療
MX2019005089A (es) * 2016-11-02 2019-09-10 Apexigen Inc Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso.
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
EP3569616B1 (en) * 2017-01-13 2021-09-29 Taizhou Hanzhong Biopharmaceutics, Inc. Monoclonal antibody against pd-1 and applications thereof
JP2020510673A (ja) * 2017-03-03 2020-04-09 ヤンセン バイオテツク，インコーポレーテツド がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
CA3071217A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh Hsp70 based combination therapy
CA3093820A1 (en) * 2018-03-13 2019-09-19 Hibercell, Inc. Beta glucan and cd40 agonist combination immunotherapy
WO2019241306A2 (en) * 2018-06-12 2019-12-19 Neon Therapeutics, Inc. Combination therapy with neoantigen vaccine
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020104690A1 (en) 2018-11-23 2020-05-28 Quine Medical Ab Bi-specific conjugates
US20220025060A1 (en) * 2018-11-30 2022-01-27 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2022534494A (ja) * 2019-05-28 2022-08-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ４０抗体の安全な投与を提供する方法
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
WO2021132936A1 (ko) * 2019-12-27 2021-07-01 인터올리고 주식회사 암 치료용 면역 항암 조성물
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023064878A1 (en) * 2021-10-15 2023-04-20 The Rockefeller University Combination of anti-cd40 antibody and il-15 for treating cancer
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
ATE295882T1 (de) 2000-12-12 2005-06-15 Alligator Bioscience Ab Eine methode zur in vitro molekularen evolution der proteinfunktion
EP2009027B1 (en) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
CA2485506C (en) 2002-05-17 2012-02-28 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
ES2354865T3 (es) 2005-05-26 2011-03-18 Seattle Genetics, Inc. Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
WO2010024676A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2951209A4 (en) * 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
WO2015091655A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Combination therapy with an anti-ang2 antibody and a cd40 agonist
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
UY36692A (es) 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
EA035268B1 (ru) 2015-06-29 2020-05-22 Бристол-Маерс Сквибб Компани Антитела к cd40

Also Published As

Publication number Publication date
CA2957146A1 (en) 2016-02-18
WO2016023960A1 (en) 2016-02-18
CN114099671A (zh) 2022-03-01
NZ729270A (en) 2024-03-22
EA201790339A1 (ru) 2017-06-30
PH12017500229A1 (en) 2017-07-10
MX2017001864A (es) 2017-08-02
KR20170041790A (ko) 2017-04-17
EP3180087B1 (en) 2019-03-13
UA119783C2 (uk) 2019-08-12
NI201700015A (es) 2017-05-12
ES2725463T3 (es) 2019-09-24
AU2015303164A1 (en) 2017-03-09
US20210403589A1 (en) 2021-12-30
CL2017000335A1 (es) 2017-08-11
AU2015303164B2 (en) 2020-10-29
CO2017001317A2 (es) 2017-08-10
MA47472A (fr) 2019-12-18
EP3552665A2 (en) 2019-10-16
SG11201701070WA (en) 2017-03-30
DK3180087T3 (da) 2019-05-13
IL250512A0 (en) 2017-03-30
US20240132609A1 (en) 2024-04-25
ECSP17008984A (es) 2017-05-31
SV2017005380A (es) 2018-09-14
US11149090B2 (en) 2021-10-19
CN106573981A (zh) 2017-04-19
JP2017524715A (ja) 2017-08-31
JP6654187B2 (ja) 2020-02-26
EP3180087A1 (en) 2017-06-21
IL250512B (en) 2021-08-31
US20170226217A1 (en) 2017-08-10
EP3552665A3 (en) 2019-12-18
PE20170680A1 (es) 2017-06-14
KR102443258B1 (ko) 2022-09-14
BR112017002729A2 (pt) 2018-02-27

Similar Documents

Publication Publication Date Title
CR20170096A (es) Tratamientos conjuntos con anticuerpos anti cd40
CO2018000809A2 (es) Anticuerpos para cd40
PH12021550023A1 (en) Humanized anti-tau antibodies
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
CL2019000146A1 (es) Anticuerpos anti - gprc5d, moléculas de unión de antigeno bioespecificos que enlazan gprc5d y cd3, y usos relacionados.
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
BR112016005303A2 (pt) anticorpos anti-b7-h1 para tratamento de tumores
GEP20237466B (en) Methods of inhibiting angiogenesis in patient
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
CR20180250A (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y uso de estas
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
CO2019010164A2 (es) Anticuerpos que se unen a steap-1
EA201791970A1 (ru) Способ лечения первичного склерозирующего холангита
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
EA201891445A1 (ru) Молекулы антител, которые связываются с tnf-альфа
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
NZ725519A (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
AR106535A1 (es) Modulación y tratamiento inmunes de tumores sólidos con anticuerpos que se unen específicamente a cd38